Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuronal nicotinic acetylcholine receptor alpha-7 subunit (α7 nAChR)
- Target
- α7 nAChR
- Molecular classification
- Ligand-gated ion channel, Cys-loop receptor family, Ion channel, Receptor
01
Overview
The neuronal nicotinic acetylcholine receptor alpha-7 subunit (α7 nAChR) is a ligand-gated ion channel belonging to the Cys-loop receptor family, widely expressed in the central nervous system and peripherally. It assembles as a homopentamer and is exceptionally permeable to calcium ions (Ca²⁺). When activated by endogenous ligands such as acetylcholine or exogenous compounds like nicotine, the α7 nAChR mediates fast synaptic neurotransmission and modulates a wide range of physiological processes, including cognitive function, neuroprotection, and inflammation. Its rapid desensitization kinetics, allosteric modulator binding sites, and distinct biophysical properties have made α7 a major research and therapeutic target for neurodegenerative and neuropsychiatric disorders, as well as for cognitive enhancement and anti-inflammatory interventions[1][2][3][5].
- Other names
- Alpha-7 nicotinic acetylcholine receptor subunitα7 nicotinic receptorCHRNA7 (gene symbol)nAChR α7
02
Mechanism of action
Agonism: direct activation of the receptor by ligands (agonists)\n- Positive allosteric modulation: enhancement of receptor response by modulators (e.g., PNU-120596)\n- Antagonism: blockade of receptor function by antagonists (e.g., α-bungarotoxin)\n- Partial agonism
03
Biological functions
Fast synaptic neurotransmissionCalcium signaling (Ca²⁺ permeable)Modulation of inflammation (cholinergic anti-inflammatory pathway)Cognitive function and neuroplasticity
04
Disease associations
Neurodegenerative diseaseSchizophreniaCognitive impairment (including Alzheimer’s disease)InflammationEpilepsyOther central nervous system disorders
05
Safety considerations
Rapid desensitization leading to tachyphylaxis (loss of efficacy during chronic agonist exposure)[1][2]Off-target CNS effects (e.g., seizures at high agonist doses)Potential cardiovascular risks (less frequent)Difficulty achieving selectivity due to similarity with other nAChR subtypes
06
Interacting drugs
Nicotine
7 more in the full profile.
07
Biomarkers
Expression levels of CHRNA7 mRNA or protein in central nervous system tissueReceptor occupancy with radiolabeled ligands (e.g., PET imaging with α7-selective tracers; research use)Circulating inflammatory cytokine levels (as indirect readout in trials targeting inflammation)
Beyond the preview
Go deeper on Neuronal nicotinic acetylcholine receptor alpha-7 subunit (α7 nAChR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuronal nicotinic acetylcholine receptor alpha-7 subunit (α7 nAChR).